. Author manuscript; available in PMC: 2014 Sep 22.

Published in final edited form as: Cochrane Database Syst Rev. 2011 Sep 7;(9):CD009039. doi: 10.1002/14651858.CD009039.pub2

Table 1.

Data analysis summary

Outcome	Effect estimate
Quality of life (SGRQ)	MD −1.02; 95% CI −5.10 to 3.06
Number of patients with ≥1 exacerbations	OR 0.81; 95% CI 0.51 to 1.30
Number of patients suffering from pneumonia	OR 1.02; 95% CI 0.06 to 16.48
Mortality	OR 1.02; 95% CI 0.32 to 3.24
Number of patients with ≥1 hospitalisations (all cause)	OR 0.91; 95% CI 0.53 to 1.58
Number of patients with ≥1 hospitalisations due to exacerbations	OR 0.63; 95% CI 0.34 to 1.17
Pre-dose FEV₁	MD 0.07; 95% CI −0.03 to 0.17
Number of patients suffering ≥1 serious adverse events (non-fatal)	OR 1.02; 95% CI 0.20 to 5.14
Number of patients suffering ≥1 adverse events	OR 1.58; 95% CI 0.93 to 2.68
Total number of patients withdrawn	OR 0.45; 95% CI 0.27 to 0.74
Number of patients withdrawn due to adverse events	OR 1.38; 95% CI 0.47 to 4.09
Number of patients withdrawn due to lack of efficacy	OR 0.36; 95% CI 0.21 to 0.63